Valuation: Protalix BioTherapeutics, Inc.

Market Cap 179M 157M 145M 135M 254M 16.88B 259M 1.74B 673M 8.32B 672M 657M 28.91B P/E 2026 *
11.4x
P/E 2027 * 44.4x
Enterprise Value 179M 157M 145M 135M 254M 16.88B 259M 1.74B 673M 8.32B 672M 657M 28.91B EV / Sales 2026 *
2.28x
EV / Sales 2027 * 2.65x
Free-Float
96.12%
Yield 2026 *
-
Yield 2027 * -
1 day-0.89%
Current month+5.21%
1 month+5.71%
3 months+2.78%
6 months+25.42%
Current year+23.33%
1 week 2.13
Extreme 2.13
2.28
1 month 1.94
Extreme 1.945
2.28
Current year 1.72
Extreme 1.72
3.19
1 year 1.36
Extreme 1.36
3.19
3 years 0.82
Extreme 0.8214
3.19
5 years 0.7
Extreme 0.7
3.55
10 years 0.7
Extreme 0.7
15.15
Manager TitleAgeSince
Chief Executive Officer 58 29/06/2019
Director of Finance/CFO 58 23/08/2025
Chief Tech/Sci/R&D Officer - 31/05/2024
Director TitleAgeSince
Director/Board Member 73 30/06/2008
Director/Board Member 82 31/10/2014
Director/Board Member 58 29/06/2019
Date Insider Type Main position Quantity % Market Cap.
12-18Buy

Chief Executive Officer

56,000 0.0696%
11-17Sell

Director

168 0.0002%
02/09/25Free

Director

22,500 0.0282%
Change 5-day change 1-year change 3-year change Capi.($)
-0.89%0.00%+57.45%-0.89% 179M
+0.93%+2.65%+42.33%+145.77% 1,006B
+1.61%+7.22%+60.81%+47.98% 589B
+3.51%+12.31%+31.15%+78.88% 430B
-0.79%+5.11%+29.26%+21.27% 331B
-0.43%+5.90%+38.16%+24.11% 288B
-1.32%+5.26%+29.68%+40.04% 285B
-2.22%+5.62%-28.21%-42.44% 213B
+0.40%+4.51%+25.85%+55.35% 190B
-1.05%+0.06%+16.91%+59.86% 154B
Average -0.02%+6.45%+30.34%+42.99% 348.59B
Weighted average by Cap. +0.60%+5.38%+35.13%+70.24%

Financials

2026 *2027 *
Net sales 78.3M 68.78M 63.37M 59.25M 111M 7.39B 113M 760M 294M 3.64B 294M 288M 12.66B 67.56M 59.35M 54.68M 51.13M 95.89M 6.38B 97.65M 656M 254M 3.14B 254M 248M 10.92B
Net income 15.72M 13.81M 12.72M 11.9M 22.31M 1.48B 22.72M 153M 59.13M 731M 59.04M 57.75M 2.54B 4.07M 3.58M 3.3M 3.08M 5.78M 384M 5.89M 39.55M 15.32M 189M 15.3M 14.96M 658M
Net Debt - -
Logo Protalix BioTherapeutics, Inc.
Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.
Employees
226
Date Price Change Volume
25/06/26 US$2.220 -0.89% 395,757
24/06/26 US$2.240 +3.23% 796,722
23/06/26 US$2.170 +0.46% 347,441
22/06/26 US$2.160 -2.70% 723,457
18/06/26 US$2.220 +9.90% 1,832,869
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.220USD
Average target price
11.00USD
Spread / Average Target
+395.50%

Quarterly revenue - Rate of surprise